CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
Every year at the CCTG Spring Meeting we recognize individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. Presentation of the awards will happen at the Recognition Awards Ceremony on Friday May 3 from 5:30 to 6:00 at the Chelsea Hotel in Toronto. We are honored to acknowledge the 2019 CCTG Recognition Awards winners.
Updated results of the CCTG MAC.7 | SWOG 0226 study have recently been published in the New England Journal of Medicine. Long-term results of a phase III trial showed that women with metastatic hormone-sensitive breast cancer lived nearly 8 months longer with the addition of fulvestrant (Faslodex) to first-line anastrozole (Arimidex).
ALC.6 (A041501), A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL, has been centrally activated.
About the trial
All participants at our member sites will be required to attest to the completion of this one-time training requirement by April 30, 2019.
Dr Lacey Pitre is an Oncologist and CCTG researcher at the Northeast Cancer Centre in Sudbury, she spoke at a press conference earlier this month to help kick off the Canadian Cancer Society's Daffodil Campaign in Northern Ontario.
The MA36 study team would like to thank everyone who helped them reach the 34 patient accrual goal for this important study.
MA36 is a Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
